FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1547234082> ?p ?o ?g. }

• W1547234082 endingPage "E68" @default.
• W1547234082 startingPage "E64" @default.
• W1547234082 abstract "Study Type – Diagnostic (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Focal therapy is an emergent therapeutic option for prostate cancer. Focal therapy includes a variety of therapeutic approaches ranging from lesion treatment to sub-total gland treatment. In this context, an accurate selection of patients having unilateral prostate cancer is closely related to the success of these strategies, especially when a hemi-ablative approach is considered. As prostate cancer is often multifocal, the critical issue is whether it is possible to preoperatively predict a clinically significant unifocal and/or unilateral lesion with sufficient accuracy to recommend focal or hemi-ablative therapy, relying on clinical characteristics and pathological data derived from the biopsy. Our study clearly demonstrates that the prediction of unilateral prostate cancer is not accurate, based on preoperative variables (predictive accuracy 52.3%). Our study is the first study based on an extended biopsy template. Even in patients diagnosed with extended biopsy, the accuracy of the available predictors is far from the ideal prediction. To date, there is no way of correctly identifying patients who will harbour unilateral prostate cancer based on routinely available variables. OBJECTIVE • To establish the predictors of unilateral prostate cancer in a population of patients with low risk prostate cancer, diagnosed with extended biopsy and submitted to radical prostatectomy, potentially candidates for focal therapy. PATIENTS AND METHODS • The study included 321 consecutive patients with low risk (clinical stage T1, Gleason score 3 + 3 or less, prostate-specific antigen [PSA] < 10 ng/mL) unilateral prostate cancer diagnosed after extended biopsy who were subsequently treated with radical prostatectomy between 2002 and 2009 at a single institution. • We evaluated the rate of unilateral prostate cancers at final pathology following radical prostatectomy, defined as pT2a or pT2b stage. • Univariable and multivariable logistic regression analyses were used to identify predictors of unilateral prostate cancers. Predictive accuracy was assessed with estimates of the area under the receiver operating characteristic curve, which were subjected to 200 bootstraps to reduce overfit bias. RESULTS • At final pathology only 29.3% patients harboured unilateral prostate cancer. No significant differences in terms of age, preoperative PSA, prostate volume and percentage of positive cores were recorded between patients with unilateral prostate cancer and patients with more advanced stage (all P≥ 0.07). • Patients harbouring unilateral prostate cancer had a smaller number of positive biopsy cores (2.8 vs 3.2, P= 0.056) compared with patients with stage pT2c or higher at final pathology. Patients with unilateral prostate cancer had a higher rate of Gleason sum 6 compared with patients with more advanced pathological stage (pT2c or higher: 85.1% vs 65.6%; P= 0.002). • On multivariable analyses, only the percentage of positive cores (odds ratio 0.57; P= 0.047) was an independent predictor of unilateral prostate cancer at radical prostatectomy, after controlling for age, PSA at diagnosis and prostate volume (all P≥ 0.3). The newly developed model for identifying the presence of unilateral prostate cancer failed to achieve accurate prediction (area under the curve 52.3%). • When only patients with a single positive core were considered, no differences in PSA and prostate volume were detected (all P≥ 0.5) and a similar rate of unilateral prostate cancer was demonstrated (33.3% vs 28.4%; P= 0.5). CONCLUSIONS • In patients with unilateral low risk prostate cancer at biopsy, only one-third showed unilateral prostate cancer at radical prostatectomy. • The number of cores and the number of positive cores represented independent predictors of unilateral prostate cancer. However, the accuracy of the multivariable model in predicting unilateral prostate cancer is low (52.3%), thus making prediction of unilateral prostate cancer extremely inaccurate. • These results need to be taken into account in those cases where focal therapy is considered as a treatment of prostate cancer." @default.
• W1547234082 created "2016-06-24" @default.
• W1547234082 creator A5031550729 @default.
• W1547234082 creator A5038974730 @default.
• W1547234082 creator A5039363062 @default.
• W1547234082 creator A5051984796 @default.
• W1547234082 creator A5053374936 @default.
• W1547234082 creator A5054660525 @default.
• W1547234082 creator A5057587736 @default.
• W1547234082 creator A5061623935 @default.
• W1547234082 creator A5071652086 @default.
• W1547234082 creator A5088744931 @default.
• W1547234082 creator A5089465716 @default.
• W1547234082 date "2011-11-17" @default.
• W1547234082 modified "2023-10-18" @default.
• W1547234082 title "Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy" @default.
• W1547234082 cites W1551087583 @default.
• W1547234082 cites W1833127314 @default.
• W1547234082 cites W1975682108 @default.
• W1547234082 cites W1977783041 @default.
• W1547234082 cites W1979940301 @default.
• W1547234082 cites W1988357742 @default.
• W1547234082 cites W1989221701 @default.
• W1547234082 cites W1996587036 @default.
• W1547234082 cites W2013940560 @default.
• W1547234082 cites W2014966452 @default.
• W1547234082 cites W2016636099 @default.
• W1547234082 cites W2030269436 @default.
• W1547234082 cites W2035765716 @default.
• W1547234082 cites W2054921086 @default.
• W1547234082 cites W2070372444 @default.
• W1547234082 cites W2074359793 @default.
• W1547234082 cites W2097428080 @default.
• W1547234082 cites W2101995865 @default.
• W1547234082 cites W2103263363 @default.
• W1547234082 cites W2109046819 @default.
• W1547234082 cites W2109487148 @default.
• W1547234082 cites W2112942915 @default.
• W1547234082 cites W2127423431 @default.
• W1547234082 cites W2138084306 @default.
• W1547234082 cites W2138105800 @default.
• W1547234082 cites W2141101208 @default.
• W1547234082 cites W2154870334 @default.
• W1547234082 cites W2171715173 @default.
• W1547234082 doi "https://doi.org/10.1111/j.1464-410x.2011.10762.x" @default.
• W1547234082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22093108" @default.
• W1547234082 hasPublicationYear "2011" @default.
• W1547234082 type Work @default.
• W1547234082 sameAs 1547234082 @default.
• W1547234082 citedByCount "33" @default.
• W1547234082 countsByYear W15472340822013 @default.
• W1547234082 countsByYear W15472340822014 @default.
• W1547234082 countsByYear W15472340822015 @default.
• W1547234082 countsByYear W15472340822016 @default.
• W1547234082 countsByYear W15472340822017 @default.
• W1547234082 countsByYear W15472340822018 @default.
• W1547234082 countsByYear W15472340822019 @default.
• W1547234082 countsByYear W15472340822020 @default.
• W1547234082 countsByYear W15472340822021 @default.
• W1547234082 countsByYear W15472340822023 @default.
• W1547234082 crossrefType "journal-article" @default.
• W1547234082 hasAuthorship W1547234082A5031550729 @default.
• W1547234082 hasAuthorship W1547234082A5038974730 @default.
• W1547234082 hasAuthorship W1547234082A5039363062 @default.
• W1547234082 hasAuthorship W1547234082A5051984796 @default.
• W1547234082 hasAuthorship W1547234082A5053374936 @default.
• W1547234082 hasAuthorship W1547234082A5054660525 @default.
• W1547234082 hasAuthorship W1547234082A5057587736 @default.
• W1547234082 hasAuthorship W1547234082A5061623935 @default.
• W1547234082 hasAuthorship W1547234082A5071652086 @default.
• W1547234082 hasAuthorship W1547234082A5088744931 @default.
• W1547234082 hasAuthorship W1547234082A5089465716 @default.
• W1547234082 hasBestOaLocation W15472340821 @default.
• W1547234082 hasConcept C121608353 @default.
• W1547234082 hasConcept C126322002 @default.
• W1547234082 hasConcept C126838900 @default.
• W1547234082 hasConcept C126894567 @default.
• W1547234082 hasConcept C146357865 @default.
• W1547234082 hasConcept C151730666 @default.
• W1547234082 hasConcept C2775934546 @default.
• W1547234082 hasConcept C2776235491 @default.
• W1547234082 hasConcept C2779343474 @default.
• W1547234082 hasConcept C2779466945 @default.
• W1547234082 hasConcept C2780192828 @default.
• W1547234082 hasConcept C2781217009 @default.
• W1547234082 hasConcept C2781406297 @default.
• W1547234082 hasConcept C71924100 @default.
• W1547234082 hasConcept C86803240 @default.
• W1547234082 hasConceptScore W1547234082C121608353 @default.
• W1547234082 hasConceptScore W1547234082C126322002 @default.
• W1547234082 hasConceptScore W1547234082C126838900 @default.
• W1547234082 hasConceptScore W1547234082C126894567 @default.
• W1547234082 hasConceptScore W1547234082C146357865 @default.
• W1547234082 hasConceptScore W1547234082C151730666 @default.
• W1547234082 hasConceptScore W1547234082C2775934546 @default.
• W1547234082 hasConceptScore W1547234082C2776235491 @default.
• W1547234082 hasConceptScore W1547234082C2779343474 @default.
• W1547234082 hasConceptScore W1547234082C2779466945 @default.

• next